ArticleInternational journal of cancer2021
African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer.
Article in International journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01221168 (ProGene), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ProGene: Etude Genetique et Epidemiologique du Cancer de la Prostate Familial
Who cites it
17 citing papers in PubMed, 37 citations in OpenAlex.
- Incorporating external risk information with the Cox model under population heterogeneity: applications to trans-ancestry polygenic hazard scores.Journal of the Royal Statistical Society. Series A, (Statistics in Society) · 2026Article
- Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study.Nature cancer · 2026Article
- Understanding Racial Disparities in Prostate Cancer: A Multifaceted Approach.Cancer medicine · 2025Review
- Racial disparity in the genomics of precision oncology of prostate cancer.Cancer reports (Hoboken, N.J.) · 2023Review
- Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.Journal of the National Cancer Institute · 2023Article
- PRState: Incorporating genetic ancestry in prostate cancer risk scores for men of African ancestry.BMC cancer · 2022Article
- Testing the generalizability of ancestry-specific polygenic risk scores to predict prostate cancer in sub-Saharan Africa.Genome biology · 2022Article
- Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies.Prostate cancer and prostatic diseases · 2022Review
- Precision intervention for prostate cancer: Re-evaluating who is at risk.Cancer letters · 2022Review
- Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.British journal of cancer · 2022Review
- Genetic Stratification of Age-Dependent Parkinson's Disease Risk by Polygenic Hazard Score.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Using Polygenic Hazard Scores to Predict Age at Onset of Alzheimer's Disease in Nordic Populations.Journal of Alzheimer's disease : JAD · 2022Article
- Polygenic risk scores: the future of cancer risk prediction, screening, and precision prevention.Medical review (2021) · 2021Review
- SNPxE: SNP-environment interaction pattern identifier.BMC bioinformatics · 2021Article
- Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men.Prostate cancer and prostatic diseases · 2021Article
- Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.Prostate cancer and prostatic diseases · 2021Article
- Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.Nature communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors at 20 institutions in 6 countries.
Funding
Abstract
Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our model developed in Europeans (PHS46) showed reduced performance in men with African genetic ancestry. We used a cross-validated search to identify single nucleotide polymorphisms (SNPs) that might improve performance in this population. Anonymized genotypic data were obtained from the PRACTICAL consortium for 6253 men with African genetic ancestry. Ten iterations of a 10-fold cross-validation search were conducted to select SNPs that would be included in the final PHS46+African model. The coefficients of PHS46+African were estimated in a Cox proportional hazards framework using age at diagnosis as the dependent variable and PHS46, and selected SNPs as predictors. The performance of PHS46 and PHS46+African was compared using the same cross-validated approach. Three SNPs (rs76229939, rs74421890 and rs5013678) were selected for inclusion in PHS46+African. All three SNPs are located on chromosome 8q24. PHS46+African showed substantial improvements in all performance metrics measured, including a 75% increase in the relative hazard of those in the upper 20% compared to the bottom 20% (2.47-4.34) and a 20% reduction in the relative hazard of those in the bottom 20% compared to the middle 40% (0.65-0.53). In conclusion, we identified three SNPs that substantially improved the association of PHS46 with age at diagnosis of prostate cancer in men with African genetic ancestry to levels comparable to Europeans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.